Search Results - "Holleran, Julianne"

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma by Burton, Jenna H, Mazcko, Christina, LeBlanc, Amy, Covey, Joseph M, Ji, Jiuping, Kinders, Robert J, Parchment, Ralph E, Khanna, Chand, Paoloni, Melissa, Lana, Sue, Weishaar, Kristen, London, Cheryl, Kisseberth, William, Krick, Erika, Vail, David, Childress, Michael, Bryan, Jeffrey N, Barber, Lisa, Ehrhart, E J, Kent, Michael, Fan, Timothy, Kow, Kelvin, Northup, Nicole, Wilson-Robles, Heather, Tomaszewski, Joseph, Holleran, Julianne L, Muzzio, Miguel, Eiseman, Julie, Beumer, Jan H, Doroshow, James H, Pommier, Yves

“…Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their…”
Get full text

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma by Badros, Ashraf, Burger, Angelika M, Philip, Sunita, Niesvizky, Ruben, Kolla, Sarah S, Goloubeva, Olga, Harris, Carolynn, Zwiebel, James, Wright, John J, Espinoza-Delgado, Igor, Baer, Maria R, Holleran, Julianne L, Egorin, Merrill J, Grant, Steven

“…Purpose: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro . We sought to test the combination…”
Get full text

Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E max regressions by Beumer, Jan H, Kennard, Benjamin C, Holleran, Julianne L, Moore, Nancy, Zlott, Jennifer, Miller, Brian M, Kummar, Shivaani, Chen, Alice, Doroshow, James, Park, Wansu, Gobburu, Jogarao, Dunn, Allison

“…This study aimed at characterizing indotecan population pharmacokinetics and explore the indotecan-neutropenia relationship in patients with solid tumors…”
Get full text

Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions by Beumer, Jan H., Kennard, Benjamin C., Holleran, Julianne L., Moore, Nancy, Zlott, Jennifer, Miller, Brian M., Kummar, Shivaani, Chen, Alice, Doroshow, James, Park, Wansu, Gobburu, Jogarao, Dunn, Allison

“…Purpose This study aimed at characterizing indotecan population pharmacokinetics and explore the indotecan–neutropenia relationship in patients with solid…”
Get full text

Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry by Orleni, Marco, Parise, Robert A., Holleran, Julianne L., Amengual, Jennifer E., Feng, Ye, Synold, Timothy, Beumer, Jan H.

“…To support a phase 1 trial in patients with lymphomas, we developed a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for tazemetostat…”
Get full text

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS by Kim, Kyu-pyo, Parise, Robert A., Holleran, Julianne L., Lewis, Lionel D., Appleman, Leonard, van Erp, Nielka, Morris, Michael J., Beumer, Jan H.

“…[Display omitted] •Bicalutamide, enzalutamide and abiraterone target the androgen receptor pathway.•A phase 3 trial of enzalutamide and abiraterone in…”
Get full text

Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701) by Ruddy, Kathryn J., Zahrieh, David, He, Jun, Waechter, Blake, Holleran, Julianne L., Lewis, Lionel D., Chow, Selina, Beumer, Jan, Weiss, Matthias, Trikalinos, Nikolaos, Faller, Bryan, Lustberg, Maryam, Rugo, Hope S., Loprinzi, Charles

“…mTOR inhibitors such as everolimus may cause oral stomatitis, often a dose-limiting toxicity. Prior clinical research has suggested that a dexamethasone mouth…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors by RAMANATHAN, Ramesh K, EGORIN, Merrill J, ERLICHMAN, Charles, REMICK, Scot C, RAMALINGAM, Suresh S, NARET, Cynthia, HOLLERAN, Julianne L, TENEYCK, Cynthia J, PERCY IVY, S, BELANI, Chandra P

“…To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)…”
Get full text

Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC–MS/MS by Holleran, Julianne L., Parise, Robert A., Guo, Jianxia, Kiesel, Brian F., Taylor, Sarah E., Ivy, S. Percy, Chu, Edward, Beumer, Jan H.

“…•Iohexol is a widely used marker for measuring glomerular filtration rate (GFR).•Accurate GFR measurement is important in treatment decisions in oncology.•We…”
Get full text

Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker by Joshi, Anand, Guo, Jianxia, Holleran, Julianne L., Kiesel, Brian, Taylor, Sarah, Christner, Susan, Parise, Robert A., Miller, Brian M., Ivy, S. Percy, Chu, Edward, Venkataramanan, Raman, Beumer, Jan H.

“…Purpose Carboplatin dose is calculated based on kidney function, commonly estimated with imperfect creatinine-based formulae. Iohexol is used to measure…”
Get full text

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas by STATHIS, Anastasios, HOTTE, Sebastien J, WANG, Lisa, ZHANG, Wen-Jiang, ESPINOZA-DELGADO, Igor, HOLLERAN, Julianne L, EGORIN, Merrill J, SIU, Lillian L, CHEN, Eric X, HIRTE, Holger W, OZA, Amit M, MORETTO, Patricia, WEBSTER, Sheila, LAUGHLIN, Anne, STAYNER, Lee-Anne, MCGILL, Shauna

“…This phase I study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of decitabine with vorinostat. Patients…”
Get full text

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study by RAMALINGAM, Suresh S, KUMMAR, Shivaani, IVY, S. Percy, BELANI, Chandra P, EGORIN, Merrill J, SARANTOPOULOS, John, SHIBATA, Stephen, LORUSSO, Patricia, YERK, Mara, HOLLERAN, Julianne, YAN LIN, BEUMER, Jan H, HARVEY, R. Donald

“…Vorinostat is the first US Food and Drug Administration-approved histone deacetylase inhibitor and is indicated for the treatment of refractory cutaneous…”
Get full text

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors by Kummar, Shivaani, Chen, Alice, Gutierrez, Martin, Pfister, Thomas D., Wang, Lihua, Redon, Christophe, Bonner, William M., Yutzy, William, Zhang, Yiping, Kinders, Robert J., Ji, Jiuping, Allen, Deborah, Covey, Joseph M., Eiseman, Julie L., Holleran, Julianne L., Beumer, Jan H., Rubinstein, Larry, Collins, Jerry, Tomaszewski, Joseph, Parchment, Ralph, Pommier, Yves, Doroshow, James H.

“…Purpose Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that overcome the limitations of camptothecins: chemical instability and…”
Get full text

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis by Eads, Jennifer R., Beumer, Jan H., Negrea, Lavinia, Holleran, Julianne L., Strychor, Sandra, Meropol, Neal J.

“…Background Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal…”
Get full text

LC–MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma by Holleran, Julianne L., Eiseman, Julie L., Parise, Robert A., Kummar, Shivaani, Beumer, Jan H.

“…[Display omitted] •FdCyd is a DNA methylation inhibitor undergoing Phase I and II trials.•An LC–MS/MS assay from 5 to 3000ng/mL in 0.2mL plasma was…”
Get full text

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer by FAKIH, Marwan G, PENDYALA, Lakshmi, EGORIN, Merrill J, FETTERLY, Gerald, TOTH, Karoli, ZWIEBEL, James A, ESPINOZA-DELGADO, Igor, LITWIN, Alan, RUSTUM, Youcef M, ROSS, Mary Ellen, HOLLERAN, Julianne L

“…Purpose: We conducted a phase I study to determine the maximum tolerated dose of vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin,…”
Get full text

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103) by Beumer, Jan H., Owzar, Kouros, Lewis, Lionel D., Jiang, Chen, Holleran, Julianne L., Christner, Susan M., Blum, William, Devine, Steven, Kolitz, Jonathan E., Linker, Charles, Vij, Ravi, Alyea, Edwin P., Larson, Richard A., Ratain, Mark J., Egorin, Merrill J.

“…Purpose Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens…”
Get full text

Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans by Holleran, Julianne L., Beumer, Jan H., McCormick, David L., Johnson, William D., Newman, Edward M., Doroshow, James H., Kummar, Shivaani, Covey, Joseph M., Davis, Myrtle, Eiseman, Julie L.

“…Introduction 5-Fluoro-2′-deoxycytidine (FdCyd; NSC48006), a fluoropyrimidine nucleoside inhibitor of DNA methylation, is degraded by cytidine deaminase (CD)…”
Get full text

A liquid chromatography–electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum by Parise, Robert A., Holleran, Julianne L., Beumer, Jan H., Ramalingam, Suresh, Egorin, Merrill J.

“…Vorinostat (suberoylanilide hydroxamic acid, SAHA) is undergoing evaluation as an antineoplastic agent. We developed a liquid chromatography–tandem mass…”
Get full text

Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring by Kozo, Daniel, Ross, Matt W, Jarrah, Justin, Barrett, Michael, Harney, Rebecca L, Courtney, Jodi B, Baburina, Irina, Holleran, Julianne L, Beumer, Jan H, Peters, Godefridus J, Honeywell, Richard J, Salamone, Salvatore J

“…Gemcitabine (2',2'-difluoro-2'-deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid…”
Get full text